IA期浸润性黏液腺癌术后生存与肿瘤学特征
本研究回顾性分析三家机构1228例病理IA期肺腺癌(排除pT1mi)手术患者,其中浸润性黏液腺癌100例、非黏液腺癌1128例,经倾向评分匹配后比较生存。匹配后5年总生存率分别为90.4%和92.7%,5年无复发生存率分别为83.7%和93.3%,生存曲线无显著差异。结论认为病理IA期浸润性黏液腺癌术后预后与非黏液腺癌相当,黏液组织学本身不应视为早期不良预后因素。
要点
- IA期浸润性黏液腺癌术后5年总生存率与非黏液腺癌相当。
- 匹配后5年无复发生存率黏液组83.7%、非黏液组93.3%,差异无统计学意义。
- 早期黏液组织学本身不应视为不良预后因素。
核心结论
- 病理IA期浸润性黏液腺癌术后预后与非黏液腺癌相当,黏液组织学本身不应视为早期不良预后因素。
研究设计与样本
- 回顾性研究,纳入三家机构病理IA期肺腺癌手术患者(排除pT1mi),共1228例,其中非黏液腺癌1128例、浸润性黏液腺癌100例,采用倾向评分匹配减少基线失衡。
主要发现
- 匹配前,浸润性黏液腺癌与更小的病理全肿瘤尺寸、更大的病理浸润肿瘤尺寸及更低的淋巴血管侵犯频率显著相关。
- 匹配前5年总生存率黏液组92.5%、非黏液组92.7%,5年无复发生存率分别为87.5%和92.3%。
- 匹配后5年总生存率黏液组90.4%、非黏液组92.7%,5年无复发生存率分别为83.7%和93.3%,两组生存曲线无显著差异。
临床怎么用
- 对于病理IA期浸润性黏液腺癌,术后预后评估可参照非黏液腺癌,不必仅因黏液组织学而升级为不良预后因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The prognosis of invasive mucinous adenocarcinoma has not been well investigated because of its rarity, especially with regard to early-stage disease. This study aimed to compare the prognosis of early-stage invasive mucinous adenocarcinoma with that of non-mucinous adenocarcinoma and to clarify oncologic characteristics of early-stage invasive mucinous adenocarcinoma. METHODS: Patients with pathological stage IA lung adenocarcinoma, excluding pT1mi tumors, who underwent surgery at three institutions were retrospectively examined. Overall survival and recurrence-free survival were compared between patients with invasive mucinous adenocarcinoma and non-mucinous adenocarcinoma. Propensity score matching was applied to reduce baseline imbalances. RESULTS: Among the 1228 patients, 1128 had non-mucinous adenocarcinoma and 100 had invasive mucinous adenocarcinoma. Before matching, invasive mucinous adenocarcinoma was significantly associated with smaller pathological whole tumor size, larger pathological invasive tumor size and a lower frequency of lymphovascular invasion. The 5-year overall survival rates were 92.5% and 92.7%, and the 5-year recurrence-free survival rates were 87.5% and 92.3% in patients with invasive mucinous and non-mucinous adenocarcinoma, respectively. Baseline covariates including pathological tumor size and stage were generally balanced after matching. The 5-year overall survival rates were 90.4% and 92.7%, and the 5-year recurrence-free survival rates were 83.7% and 93.3%, respectively, with no significant differences in survival curves between groups. CONCLUSIONS: The postoperative prognosis of patients with pathological stage IA invasive mucinous adenocarcinoma was comparable to that of patients with non-mucinous adenocarcinoma. These findings suggest that mucinous histology alone should not be considered an adverse prognostic factor in early-stage disease.
引用
- Ueda D, Mimae T, Kudo Y, et al. Postoperative survival and oncologic characteristics of stage IA invasive mucinous adenocarcinoma. Interdiscip Cardiovasc Thorac Surg. 2026. PMID: 42820784. doi:10.1093/icvts/ivag272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。